This activity is specifically designed for:
Regulators
Policy makers
At the end of the course, learners should be able to:
Explain trade-offs between accuracy, accessibility, affordability and time-to-result
Detail key considerations in balancing risks and benefits using COVID-19 tests as examples
With countries committed to universal access to health care and leaving no one behind and the need for widespread testing for the COVID-19 pandemic, we will examine how trade-offs need to be made between test accuracy, accessibility affordability and time to result using case studies. Addressing these issues, the agenda is as follows:
Accuracy vs. Access (HIV Rapid Tests)
Accuracy vs Accessibility and Time-to-Result (Early Infant Diagnosis of HIV)
Test Sensitivity vs Testing Frequency and Time-to-Result (COVID-19)
Trade-offs Between Accuracy, Accessibility, Affordability and Time-to-Result of in-vitro Diagnostics
Professor Rosanna Peeling, London School of Hygiene & Tropical Medicine, UK
Professor David Heymann, London School of Hygiene & Tropical Medicine, UK
Dr. Noah Fongwen, London School of Hygiene and Tropical Medicine & Africa CDC, UK
Scott Chiossi, Chatham House, UK
Carlos Gouvea, Latin American Alliance for In Vitro Diagnostic Development (ALADDiV), Brazil
Dr. Sidney Yee, DxD Hub, Association of Southeast Asian Nations (ASEAN), Singapore
Dr. Jaime Montoya, Council for Health Research and Development, Association of Southeast Asian Nations (ASEAN), Philippines
Add your email to the mailing list to get the latest updates.
